Breakthrough in Schizophrenia Treatment
A new digital therapeutic, CT-155, has shown promise in reducing negative symptoms of schizophrenia.
Developed by Boehringer Ingelheim and Click Therapeutics, CT-155 is a smartphone app that uses adaptive goal-setting techniques to deliver psychosocial interventions.
- Phase 3 trial results presented at the 38th Annual European College of Neuropsychopharmacology Congress demonstrated the app's efficacy.
- CT-155 is the first experimental prescription digital therapy to show good tolerability and no significant adverse events when used with antipsychotic treatment.
No significant adverse events were reported when CT-155 was administered with an antipsychotic treatment.
An estimated 24 million people worldwide have schizophrenia, according to the World Health Organization, characterized by persistent delusions and hallucinations.
Author's summary: Digital therapy CT-155 reduces schizophrenia symptoms.
More News
- Tackling food waste is about 'creating beauty through respect' - Bottura - EnviroNews - latest environment news, climate change, renewable energy
- SNAP benefits at risk next month amid government shutdown
- Climate action: ILO hails Nigeria’s inclusion of workers’ voices in NDC 3.0 - EnviroNews - latest environment news, climate change, renewable energy
- Utah probation officer charged with soliciting explicit photos from supervised offender
- Just how important are set-pieces in FPL?
- I Could Never Stick With a Skin-care Device Until I Tried the TheraFace Pro
- Opinion: The container industry faces a new era – the battle for the 2030s has begun
- IVFP to propose weekend-long noise ordinance on Deltopia | The Daily Nexus
- Tassie get Shield redemption with thrilling win over WA
- Fulham v Arsenal predicted line-ups + FPL team news